The first two ICOpre® patents filed

/in , , , , /by

Iconovo AB (publ) has filed two ICOpre® patent applications.

ICOpre® is Iconovo’s new inhalation platform and builds on novel proprietary technology and unique technical solutions. For an innovative company like Iconovo it is paramount to protect its inventions and intellectual property. These two patents are the first step in building a strong patent portfolio around ICOpre. Iconovo has already 84 granted patents and 25 applications covering the other inhalation platforms.

”I am very pleased that ICOpre has reached this very important milestone. A strong protection of our intellectual property has always been Iconovo’s strategy and an absolute requirement from our customers. This is a major step forward in the development of our generic Relvar® ICOpre®”, says CTO Dr. Orest Lastow.

About ICOpre®

ICOpre® is a pre-metered multi-dose inhaler for simple once-daily treatment. It works well with all types of inhalation powders. It has an easy three-step operation; open-inhale-close, like the well-known Ellipta® inhaler from GSK. With 30 aluminum-sealed doses, it provides one month of treatment. Each dose comes from two different cavities that are inhaled simultaneously, making ICOpre suitable for mono, duo and triple products. ICOpre has a precise dose-counter that shows the number of doses remaining. ICOpre is being developed based on a unique principle that will be protected by a number of patents.
https://www.iconovo.se/products/icopre/

Contacts

Johan Wäborg, CEO
+46 707 78 51 71
johan.waborg@iconovo.se

About Iconovo

Iconovo was founded in 2013 by people with long experience in inhalation development. The company develops inhalers and associated drug preparations that are used to treat asthma and COPD. However, Iconovo also has the competence to develop products for new types of inhaled drugs such as vaccines.

By working with Iconovo, pharmaceutical companies and generic companies can access a complete pharmaceutical product, thereby eliminating the complex and costly early stages of the development phase. Iconovo licenses its patented products to customers and offers a faster way to the inhalation market with lower risk and at a lower cost.

More information about the company can be found at www.iconovo.se.

Iconovo is based in Lund and its share (ticker ICO) is listed on Nasdaq First North Growth Market, Stockholm since April 6, 2018. The Company’s Certified Adviser is Erik Penser Bank AB, Box 7405, SE-103 91 Stockholm, phone +46 8 463 80 00, email: certifiedadviser@penser.se.

Attachments

The first two ICOpre® patents filed